Johnson & Johnson to Pay $2.2 Billion Upfront to Acquire Ollin, Adding Late-Stage Eye Treatment
Key Facts
Johnson & Johnson said on November 16 that it had agreed to acquire Texas-based Ollin Biosciences for $2.2 billion upfront, plus potential payments tied to regulatory and commercial milestones. Reuters reported that the deal is expected to close before the end of 2026. The acquisition centers on OLN324, a bispecific antibody in development to treat vision-threatening eye diseases. The agreement adds a late-stage treatment to the company’s portfolio, while the additional consideration remains contingent on future milestones. The drug’s development is also linked to separate funding from Blackstone Life Sciences.
OLN324 is being developed for diabetic macular edema and wet age-related macular degeneration, two diseases that affect vision. The drug targets two biological pathways, according to the company’s description of it as a bispecific antibody. In January, Ollin announced preliminary results from a randomized Phase 1b trial that compared the drug with faricimab in more than 160 patients with one of the two diseases. The company presented the results as a head-to-head comparison of the two drug candidates, with follow-up later continuing through Week 20.
In the diabetic macular edema patient group, Ollin said the 4 mg dose of OLN324 achieved about 75% greater improvement in retinal dryness than faricimab at Week 1, and about 50% greater improvement at Week 12. It added that about 90% of patients who received the dose had no edema at Week 12, compared with 57% of those who received faricimab. These results relate to specific measures of edema and retinal dryness, as reported by the company. In March, Ollin announced completion of follow-up in the JADE trial at Week 20 and said the study included 164 patients in the United States. The reported results remain part of a clinical development program that requires additional studies before any regulatory decision.
Funding for the next stage was part of Ollin’s plans before the agreement: in June, the company raised $330 million in a Series B financing round to support global Phase 3 studies. It said at the time that studies for diabetic macular edema and wet age-related macular degeneration would begin in the second half of 2026. Under the new agreement, OLN324’s development includes separate Phase 3 funding from Blackstone Life Sciences, along with the possibility of milestone payments and royalties for Blackstone. This arrangement funds the trials through a party separate from the upfront acquisition payment, while tying some returns to development results and commercial and regulatory milestones. The drug’s commercial value will depend on the outcomes of the trials and regulatory reviews.
Ollin was founded in 2023 to develop treatments for vision-threatening diseases and is backed by investment firms ARCH Venture Partners and Mubadala Capital, Reuters reported. In June, Reuters said Ollin had raised $330 million to advance OLN324’s late-stage studies. Before the official announcement, Reuters reported on November 15 on terms that had been circulating, but said it could not verify the report on which they were based. EL7 data show Johnson & Johnson shares closed at $285.75 on November 13, a date before the deal announcement. The deal is expected to close before the end of 2026, according to Reuters.